Drug Combination Details
| General Information of the Combination (ID: C06862) | |||||
|---|---|---|---|---|---|
| Name | Schisandrol B NP Info | + | Doxorubicin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Healthy individual
[ICD-11: N.A.]
|
Investigative | [1] | ||
|
Cardiomyopathy
[ICD-11: BC43]
|
Investigative | [2] | |||
|
Breast cancer
[ICD-11: 2C60]
|
Investigative | [3] | |||
|
Ovarian cancer
[ICD-11: 2C73]
|
Investigative | [3] | |||
|
Hepatocellular carcinoma
[ICD-11: 2C12]
|
Investigative | [3] | |||
|
Lung cancer
[ICD-11: 2C25]
|
Investigative | [4] | |||
| Click to Show/Hide the Whole Disease Information of This Combination | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [4] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CDH1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | MMP-9 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | VIM | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
| In-vivo Model | About 1.5 * 106 human A549 tumor cells suspended in 200 ul RPMI-1640 were injected into the right forelimb of BALB/c nude mice to establish the tumor-bearing mice model. | |||||
| Experimental
Result(s) |
Schisandrin B can not only enhanced the cytotoxicity of doxorubicin, but also inhibited the invasion and metastasis of tumors in an all-round way. | |||||
| β. Decreasing Adverse Drug Reaction by This Combination | ||||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | ABCB1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | MSH3 | Molecule Info |
Pathway MAP
|
||
| In-vivo Model | Male ICR mice (18-22 g) and male Sprague-Dawley rats (300-350 g) were used in this study. | |||||
| Experimental
Result(s) |
Schisandrin B prevents doxorubicin-induced cardiotoxicity via enhancing glutathione redox cycling. | |||||
| Experiment 2 Reporting the Effect of This Combination | [5] | |||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP9 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | SMMC-7721 | CVCL_0534 | Hepatocellular carcinoma | Homo sapiens | ||
| MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Sch B may bring benefit to clinical chemotherapy by reducing significantly the cumulative doses of DOX and its associated cardiotoxicities. | |||||
| Experiment 3 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | NOX5 | Molecule Info | ||
| Down-regulation | Phosphorylation | TP53 | Molecule Info |
Pathway MAP
|
||
| In-vivo Model | Male C57BL/6 JAX mice (10-12 weeks) were used to produce subacute Dox injury in mice. | |||||
| Experimental
Result(s) |
Schisandrin B prevents doxorubicin induced cardiac dysfunction by modulation of DNA damage, oxidative stress and inflammation through inhibition of MAPK/p53 signaling. | |||||
| Experiment 4 Reporting the Effect of This Combination | [6] | |||||
| In-vitro Model | CCRF S-180 II | CVCL_2874 | Mouse fibrosarcoma | Mus musculus | ||
| 4T1 | CVCL_0125 | Malignant neoplasms | Mus musculus | |||
| In-vivo Model | Balb/c mice were inoculated subcutaneously with 2*106 4T1 cells/0.2 ml PBS or S180 cells/0.2 ml PBS. | |||||
| Experimental
Result(s) |
Sch B is capable of protecting Dox-induced chronic cardiotoxicity and enhancing its anticancer activity. | |||||
| γ. Reversing Drug Resistance by This Combination | ||||||
| Reversing Drug Resistance | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [3] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | ABCB1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| A2780 | CVCL_0134 | Ovarian endometrioid adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Schisandrin B reverses doxorubicin resistance through inhibiting P-glycoprotein and promoting proteasome-mediated degradation of survivin. | |||||
